SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Intra-Cellular Therapies, Inc. Buyout

Wilmington, Delaware--(Newsfile Corp. - January 13, 2025) - Rigrodsky Law, P.A. is investigating Intra-Cellular Therapies, Inc. ("Intra-Cellular") (NASDAQ GS: ITCI) regarding possible breaches of fiduciary duties and other violations of law related to Intra-Cellular's agreement to be acquired by Johnson & Johnson. Under the terms of the agreement, Intra-Cellular shareholders will receive $132.00 per share in cash.

To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-intra-cellular-therapies-inc.

To contact Seth D. Rigrodsky or Gina M. Serra cost free, call (302) 295-5310 or email [email protected].

Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.

Attorney advertising. Prior results do not guarantee a similar outcome.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/237093

You May Also Be Interested In

• Electra Therapeutics files for proposed IPO
• Creator Network Doomers Reaches $10M Run Rate With Twenty Launch Slots Monthly
• Trinity Biotech faces Nasdaq delisting risk over market value